Articles On Immutep (ASX:IMM)
Title | Source | Codes | Date |
---|---|---|---|
The A to Z of Dr Boreham’s Crucible in 2022
The long and short of 2022 is that it was a frustrating period for the Australian biotech sector but one with its fair share of rewards as the sector’s exponents furthered worthy drugs, diagnostics, devices and doodahs. For the sixth year,... |
Stockhead | IMM | 2 years ago |
In Brief: Insurers, Healthcare, Contractors, Classifieds, Retail
Weekly broker wrap: insurers more resilient, healthcare picks, contractors remain labour-reliant, classifieds look resilient, retail braces for decline. -Climate resilience supports domestic insurance outlook-Wilsons lists healthcare sector... |
FNArena | IMM | 2 years ago |
Lithium slammed by GS, NSW close to energy deal with Federal Government: ASX closes 0.6% lower
ShareCafeLithium slammed by GS, NSW close to energy deal with Federal Government: ASX closes 0.6% lower by Peter Milios Goldman Sachs have extended their bearish views on lithium, believing that the prices are expected to decline from the... |
ShareCafe | IMM | 2 years ago |
Lithium stocks under pressure following Goldman’s comments: ASX down 0.47% at noon
ShareCafeLithium stocks under pressure following Goldman’s comments: ASX down 0.47% at noon by Lauren Hayes The Australian market is still unnerved over concerns about a possible US recession. Energy is weighing down the benchmark over fe... |
ShareCafe | IMM | 2 years ago |
Immutep (ASX:IMM) achieves commercial scale manufacturing of efti
Immutep (IMM) achieves commercial scale manufacturing of its lead product candidate, eftilagimod alpha (efti)The company completed its first 2000-litre manufacturing run of efti, a first-in-class soluble LAG-3 proteinImmutep has been workin... |
themarketherald.com.au | IMM | 2 years ago |
ASX Health Stocks: Imagion jumps 20pc after delivering positive Phase 1 results
Imagion presents positive data at world leading symposium Osteopore expands in Southeast Asia Microba expands into Italy and Portugal Imagion speaks at world-leading breast cancer symposium Imagion Biosystems (ASX:IBX) is set to rise ov... |
Stockhead | IMM | 2 years ago |
Shares dip following rate hike: ASX closes 0.5% lower
ShareCafeShares dip following rate hike: ASX closes 0.5% lower by Peter Milios The ASX has closed 0.47 per cent lower after the Reserve Bank of Australia delivered its eighth interest rate hike in a row, lifting the cash rate 25 basis hig... |
ShareCafe | IMM | 2 years ago |
Local market awaits RBA rate decision: ASX falls 0.17% at noon
ShareCafeLocal market awaits RBA rate decision: ASX falls 0.17% at noon by Lauren Hayes The Australian market has followed Wall Street’s negative lead overnight after US markets sold off on fears that the Fed will keep increasing interest... |
ShareCafe | IMM | 2 years ago |
Market Highlights: Rates day! And almost every US stock loses overnight as US economy picks up
Well, it’s rates day here in Oz, and property owners are donning their brownest pants for a likely rise. Some say 50bps is sensible. In the US, the Fed got a case to keep rising rates despite the inflationary slowdown. Stronger than expecte... |
Stockhead | IMM | 2 years ago |
The Week that Was: November 28-December 2, 2022
ShareCafeThe Week that Was: November 28-December 2, 2022 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier... |
ShareCafe | IMM | 2 years ago |
ScoPo’s Powerplays: ASX health stocks dancing to a positive tune
ASX Health sector is continuing its upward trend, marginally up this week 0.87% Sonic Healthcare announces a plan to acquire ~20% holding of Microba Life Sciences Mayne Pharma shares takes a hit after company warns it won’t hit positive e... |
Stockhead | IMM | 2 years ago |
Iron ore climbs to highest price since September: ASX closes 0.3% higher
ShareCafeIron ore climbs to highest price since September: ASX closes 0.3% higher by Peter Milios Singaporean iron ore futures have soared above the US$100 per tonne for the first time since September, resulting in gains for ASX-listed ir... |
ShareCafe | IMM | 2 years ago |
Immutep (ASX:IMM) enters second collaboration with Pfizer and Merck KGaA for INSIGHT study
Immutep (IMM) signs another collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer for a phase one clinical studyThe companies will conduct and jointly fund the INSIGHT-005 trial in Germany to evaluate Immutep’s efti product... |
themarketherald.com.au | IMM | 2 years ago |
Chinese protests over lockdowns continue: Aus shares 0.07% lower at noon
ShareCafeChinese protests over lockdowns continue: Aus shares 0.07% lower at noon by Peter Milios The global economic outlook is shaky, as growing protests in the world’s largest manufacturing nation are creating a new level of uncertaint... |
ShareCafe | IMM | 2 years ago |
ASX Health Stocks: Sonic snaps up stake in Microba, sending MAP share price 60pc higher
Sonic has taken a stake in Microba Immutep enters into second deal with Merck (Germany) and Pfizer ImpediMed has a new CEO Sonic takes strategic stake in Microba Giant healthcare stock Sonic Healthcare (ASX:SHL) has bought a stake in s... |
Stockhead | IMM | 2 years ago |
Immutep announces new collaboration for cancer treatment combination
Immutep (ASX:IMM) has announced a new clinical trial collaboration under which the Australian company's investigative LAG-3 immunotherapy, efti, will be studied with Merck and Pfizer's PBS-listed BAVENCIO (avelumab). |
BiotechDispatch | IMM | 2 years ago |
Market Highlights: China protests dampen investor mood, and 5 ASX small caps to watch on Tuesday
The ASX is set to open slightly higher on Tuesday Wall Street fell almost 2% overnight as protests in China spread Crypto lender BlockFi has filed for bankruptcy The ASX is poised to edge slightly higher on Tuesday despite a 1.5% – 1.75%... |
Stockhead | IMM | 2 years ago |
Immutep (ASX: IMM) – A Transformative Year for LAG-3 Therapies
ShareCafeImmutep (ASX: IMM) – A Transformative Year for LAG-3 Therapies Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the LAG-3 landscape, the company’s portfolio of therapies, encouraging data from the 2022 SIT... |
ShareCafe | IMM | 2 years ago |
How out of favour Biotech has a PR problem and could learn from Dr Karl
ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and... |
Stockhead | IMM | 2 years ago |
Early gains quickly wiped off: ASX closes the day 0.16% lower
ShareCafeEarly gains quickly wiped off: ASX closes the day 0.16% lower by Peter Milios All sectors except Materials and Energy are lower in today’s day of trading, as the ASX finishes 0.16 per cent or 11.70 points lower at 7146.30. Materi... |
ShareCafe | IMM | 2 years ago |
ASX Close: Shares fade as global rally falters
The ASX gave up early gains as last week’s fierce global share rally showed signs of losing momentum. The S&P/ASX 200 touched a five-month high before fading to a loss of 12 points or 0.16 per cent. The decline came as Asian mar... |
themarketherald.com.au | IMM | 2 years ago |
Market losing momentum, materials the saviour: ASX flat at noon
ShareCafeMarket losing momentum, materials the saviour: ASX flat at noon by Lauren Hayes Last week’s gains have not continued with the same momentum this morning. Materials, up 3.4 per cent, is bolstering the local market following a rise... |
ShareCafe | IMM | 2 years ago |
ASX Update: Early gains evaporate as Fed talks down outlook
The share market touched a five-month high before shedding its gains as a decline in US futures undermined a China-fuelled rally in resource stocks. The S&P/ASX 200 rallied to within four points of 7200 for the first time since June.... |
themarketherald.com.au | IMM | 2 years ago |
Immutep (ASX:IMM) receives $986k R&D tax rebate
Immutep (IMM) receives a $986,000 tax refund from the Australian government’s research and development (R&D) tax incentive programThe cash rebate is mostly for money Immutep spent on its clinical study work during its 2021 financial yea... |
themarketherald.com.au | IMM | 2 years ago |
ASX 200 rises at open; Fortescue, Champion Iron up over 8%
Highlights Australian shares opened higher on Monday. The ASX 200 gained in the opening trade, rising 25.20 points, or 0.35%, to 7,183.20. On Friday, the benchmark index closed 2.8% higher at 7,158 points. Australian s... |
Kalkine Media | IMM | 2 years ago |
Imugene (ASX:IMU) presents fresh onCARlytics data at SITC annual meeting
Imugene (IMU) presents new data for its onCARlytics oncolytic virus at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Boston, USThe company presented two different sets — the first for a treatment with fellow biotec... |
themarketherald.com.au | IMM | 2 years ago |
Immutep (ASX:IMM) granted Japanese and South Korean patents for efti
Immutep (IMM) receives two new patents from the Japanese Patent Office and South Korean Patent Office for its immunotherapy treatment for cancerThe new patent protects Immutep’s intellectual property relating to combined therapeutic prepara... |
themarketherald.com.au | IMM | 2 years ago |
A sea of red in today’s trading: ASX closes 1.84% lower
ShareCafeA sea of red in today’s trading: ASX closes 1.84% lower by Peter Milios All but one sector finished lower today, as the ASX reacted to the overnight news that the Fed has increased rates by 75 basis points. Materials, Consumer Di... |
ShareCafe | IMM | 2 years ago |
All red across the board following US rate hike sentiment: ASX down 1.96% at noon
ShareCafeAll red across the board following US rate hike sentiment: ASX down 1.96% at noon By Lauren Hayes US equities plunged after Fed Chair Jerome Powell indicated policymakers would continue raising interest rates to fight persistent... |
ShareCafe | IMM | 2 years ago |
2 ASX healthcare shares smashing the All Ords today
The All Ordinaries Index (ASX: XAO) may be sinking today but that hasnât stopped a couple of ASX healthcare shares from racing higher. Hereâs why these two All Ords shares are smashing the index on Thursday: Immutep Ltd (ASX: IMM) The... |
Motley Fool | IMM | 2 years ago |
ASX Health Stocks: HitIQ soars 40pc after signing footy deal; Rhythm Bio expands to NZ
HitIQ signs deal with Western Australian Football Commission Rhthym Bio expands into NZ Immutep’s Phase II TACTI-002 trial has been accepted for an oral presentation HitIQ signs with WAFC Concussion tech specialist HitIQ (ASX:HIQ) rose 40... |
Stockhead | IMM | 2 years ago |
Market Highlights: Two uttered words that crashed the market, and 5 ASX small caps to watch today
The ASX is set to plunge on Thursday after a crash in New York US Fed unleashed another jumbo 75bp rate hike Fed boss Jerome Powell spooked the markets during his speech The ASX is poised to plunge on Wednesday, tracking movements in Ne... |
Stockhead | IMM | 2 years ago |
ASX increases slightly ahead of today’s rate rise: Aus shares 0.3% higher at noon
ShareCafeASX increases slightly ahead of today’s rate rise: Aus shares 0.3% higher at noon by Peter Milios Last week’s rally for US equities ground to a halt overnight ahead of this week’s Federal Reserve decision on interest rates, as te... |
ShareCafe | IMM | 2 years ago |
Immutep (ASX:IMM) to continue with controlled phase IIB TACTI-003 trial for HNSCC cancer
Immutep (IMM) is given approval by the Independent Data Monitoring Committee (IDMC) to carry on with its planned phase IIb TACTI-003 trialThe IDMC reviewed the initial safety data and concluded that the trial should continue with no modific... |
themarketherald.com.au | IMM | 2 years ago |
Market unfazed by CPI data: ASX finishes 0.18% higher
ShareCafeMarket unfazed by CPI data: ASX finishes 0.18% higher by Peter Milios CPI data from the September quarter has sharply exceeded estimates. As such, multiple banks have made predictions for the next rate rise. Commonwealth Bank (AS... |
ShareCafe | IMM | 2 years ago |
Australian headline inflation hits highest in 32 years: ASX up 0.12% at noon
ShareCafeAustralian headline inflation hits highest in 32 years: ASX up 0.12% at noon by Lauren Hayes The S&P/ASX 200 posted gains this morning as sentiment from Wall Street overnight improved over the Fed potentially turning less agg... |
ShareCafe | IMM | 2 years ago |
ASX Biotech Stocks: Neurotech reports positive paediatric autism results and Arovella to close Perth R&D facility
Neurotech says its NTI164 drug for paediatric autism showed improvements in symptoms Arovella closing Perth R&D facility to focus on invariant Natural Killer T (iNKT) cell platform Argenica reports safety and efficiacy of stroke drug A... |
Stockhead | IMM | 2 years ago |
Energy and Materials only sectors left lagging: ASX closes 0.28% higher
ShareCafeEnergy and Materials only sectors left lagging: ASX closes 0.28% higher by Peter Milios In today’s events, independent commission agency ASIC has launched legal action against BPS Financial, the company behind Gold Coast-based di... |
ShareCafe | IMM | 2 years ago |
Optimism out of the US boosts sentiment: ASX up 0.6% at noon
ShareCafeOptimism out of the US boosts sentiment: ASX up 0.6% at noon by Lauren Hayes Positive gains in the local market have extended into a second day as optimism out of the US about corporate earnings ahead of several key tech reports... |
ShareCafe | IMM | 2 years ago |
Check Up: Only two healthcare IPOs from 2021 are gaining ground, could the rest be buying opportunities?
We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month There were 191 ASX IPOs in... |
Stockhead | IMM | 2 years ago |
Immutep (ASX: IMM) Receives Fast Track Designation from FDA
ShareCafeImmutep (ASX: IMM) Receives Fast Track Designation from FDA Immutep Limited (ASX: IMM) CEO and Executive Director Marc Voigt discusses the FDA fast track designation received in first-line non-small cell lung cancer, the company... |
ShareCafe | IMM | 2 years ago |
Trading Places: Chinese mining giant backs Tietto Minerals and LGI’s new substantial shareholders
Emerging gold miner Tietto Minerals has a new Chinese Mining giant as a substantial shareholder Environment play LGI has new substantial shareholders since listing on the ASX last week Lunnon Metals loses substantial shareholders while Bas... |
Stockhead | IMM | 2 years ago |
ScoPo’s Powerplays: Calmer week for ASX health stocks with some alarming stats about how many people drink instant coffee
During latest period of volatility many health stocks have seen their share prices remain quite stable Several ASX health stocks have rallied this week on positive news including Polynovo on $5 million sales month Telix Pharmaceuticals ral... |
Stockhead | IMM | 2 years ago |
Energy’s advancements just enough to lift the ASX: Aus shares close 2.2% higher
ShareCafeEnergy’s advancements just enough to lift the ASX: Aus shares close 2.2% higher by Peter Milios The ASX’s two-day positive run has turned to three days. It finished the day having increased slightly by 0.03 per cent or 1.80 point... |
ShareCafe | IMM | 2 years ago |
Second fast-track designation for Australian immunotherapy company
Australian immunotherapy company Immutep has secured fast-track designation from the US FDA for its eftilagimod alpha for use in combination with MSD's KEYTRUDA (pembrolizumab). |
BiotechDispatch | IMM | 2 years ago |
Check Up: Blood clots are a $55bn opportunity and these 2 ASX stocks are vying for a slice
Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re... |
Stockhead | IMM | 2 years ago |
Immutep (ASX:IMM) receives FDA Fast Track designation for NSCLC treatment
Immutep (IMM) receives US FDA Fast Track designation for its efti drug candidate as a treatment for non-small cell lung cancer (NSCLC)The designation — Immutep’s second for the drug — is specifically for efti when used in combination with c... |
themarketherald.com.au | IMM | 2 years ago |
ASX Health Stocks: Paradigm soars 19pc after meeting primary endpoint of Phase 2 trial
Paradigm successfully meets primary endpoint of Phase 2 trial Immutep granted Fast Track designation by the FDA ImpediMed signs strategic partnership with GenesisCare Paradigm Biopharma (ASX:PAR) surged 19% this morning after announcing t... |
Stockhead | IMM | 2 years ago |
Why did the Imugene share price implode 31% in September?
The Imugene Limited (ASX: IMU) share price had a rough month despite multiple clinical trial updates. Imugene shares have fallen 30.77% from 26 cents at market close on 31 August to 18 cents at market close on 30 September.... |
Motley Fool | IMM | 2 years ago |
Immutep (ASX:IMM) receives $2.7 million R&D French tax incentive
Immutep (IMM) receives a $2.7 million research and development tax incentive from the French GovernmentThe company received the funds under France’s research tax credit scheme, which sees eligible French companies reimbursed for 30 per cent... |
themarketherald.com.au | IMM | 2 years ago |